Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial.
The lancet. Gastroenterology & hepatology（2023）
摘要
The EU Horizon 2020 Research and Innovation Program and The Novo Nordisk Foundation.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要